Bebtelovimab for High-Risk Outpatients With Early COVID-19 in a Large US Health System
Sign Up to like & getrecommendations! Published in 2022 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofac565
Abstract: Abstract There are limited data for the clinical efficacy of bebtelovimab in preventing severe coronavirus disease 2019. Among outpatients unable to take nirmatrelvir-ritonavir at a large health system, 10 of 377 (2.7%) patients who received… read more here.
Keywords: risk; bebtelovimab high; large health; health system ... See more keywords